IRS Logo
Print - Click this link to Print this page

Qualifying Therapeutic Discovery Project Grants for the State of Maryland

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

Maryland  $ 48,745,215.69
Applicant Name Project Name Grants Awarded for 2009 Grants Awarded for 2010
20/20 GeneSystems Inc Diagnostic for the Early Detection of Lung Cancer $ 165,935.50 $ 78,543.74
20/20 GeneSystems Inc PredicTOR cancer diagnostic $ 244,479.24  
A&G Pharmaceuticals, Inc Development of Anti-GP88 Drug & Diagnostic:  Novel Therapy for Chemoresistant Cancer $ 244,479.25  
Adlyfe, Inc. Adlyfe Alzheimer's Diagnostic Assay $ 244,479.25  
Advanced Biomimetic Sensors, Inc Development of an Accurate, Pain-free and Reagent-free Blood Glucose Monitoring Device $ 73,757.09 $ 32,007.02
Akonni Biosystems, Inc. Simultaneous PCR & Microarray Detection, TruArray Test $ 244,479.25  
Akonni Biosystems, Inc. The Multiplexed Respiratory Infection POC Testing in 15 Minutes $ 244,479.25  
Alan Penn & Associates, Inc. CAD system to improve sensitivity of breast MRI using diffusion weighted imaging $ 25,376.24 $ 7,511.99
Alper Biotech LLC Biomarker Platform Technology for Breast Cancer Diagnosis and Treatment $ 116,052.70 $ 128,426.55
Ambay Immune Sensors and Controls LLC Immune Sensor for Early Detection of Breast Cancer in Blood $ 8,082.50  
American Gene Technology International Inc. Safe Lentiviral Delivery of Multiple Therapeutic Molecules for the Treatment of Cancer $ 140,816.50 $ 103,662.75
Amplimmune, Inc AMP-224 A novel Drug for the Treatment of Cancer and Infectious Disease $ 244,479.24  
Amplimmune, Inc AMP-110: A Novel Product Candidate for the Treatment of Autoimmune Disease $ 244,479.24  
AnGes, Inc Therapeutic angiogenesis with HGF plasmid (collategene)in critical limb ischemia (CLI) $ 244,479.25  
Aparna Biosciences Corporation Ligand-Targeted Lentiviral Vectors for Systemic Gene Therapy $ 161,029.00 $ 83,450.25
Aparna Biosciences Corporation Antifungal therapeutic for life-threatening invasive fungal infections $ 68,282.00 $ 27,592.00
Aparna Biosciences Corporation Nanoparticle Based Dual-antigen Anthrax Vaccine $ 52,457.50 $ 152,753.50
Aparna Biosciences Corporation In vivo targeted siRNA nanoparticles for non-small cell lung cancer $ 177,183.00 $ 67,296.25
Applied Sensor Research & Development Corporation Acoustic array biosensor for multiplexed point of care diagnosis of infectious agents $ 51,340.23 $ 80,350.34
Arcion Therapeutics, Inc ARC-2022 $ 244,479.25  
Arcion Therapeutics, Inc ARC-4558 $ 244,479.25  
Astha Consultancy, Inc Discovery of prophylactic antimalarials, oral delivery cutaneous antileishmanial and blood-brain barrier crossing Acetylcholine estrase-Organophate reactivator drugs for the war fighter $ 36,501.50 $ 50,616.00
BioAssay Works, LLC Development of Rapid, Point of Care) Diagnostics for HIV & Methicillin-Resistant Staph. $ 16,338.00 $ 6,319.50
BioAssay Works, LLC Development of rapid, Lateral-Flow and ELISA Research Assays for Kidney Injury Molecule $ 31,967.50 $ 26,555.50
BioAssay Works, LLC Development of rapid, Lateral-Flow Diagnostic Assays for Various Infectious Diseases $ 7,583.00 $ 9,674.50
BioAssay Works, LLC Modification/Conjugation of Antibodies to Thyroid Stimulating Hormone & Cardiac Troponin $ 2,795.00 $ 7,909.00
BioAssay Works, LLC Development of rapid, Lateral-Flow Diagnostic Assay to Detect PROM in pregnant women $ 12,189.50 $ 16,592.00
BioElectronics Corporation Third Molar Extraction Pain   $ 128,270.00
BIOFACTURA, INC. SMALLPOX BIODEFENSE THERAPEUTIC $ 204,793.72 $ 39,685.52
Biological Mimetics, Inc Immune Refocusing Technology $ 232,631.50 $ 11,847.75
BioMarker Strategies SnapPath™ Biomarker Testing System for Cancer   $ 244,479.25
Biospheric Incorporated Development of D-tagatose for treatment of hypertriglyceridemia   $ 225,000.00
Biospherics, Inc Development of D-tagatose oral prescription medicine for treatment of Type 2 diabetes $ 244,479.24  
BioSurface Engineering Technologies Inc BioSET F2A Reparative Mesh $ 36,325.50 $ 31,310.00
BioSurface Engineering Technologies Inc BioSET Amplex with B2A $ 244,479.25  
BioSurface Engineering Technologies, Inc BioSET PreFix with B2A $ 244,479.25  
Biosynexus Incorporated Pagibaximab $ 244,479.25  
Blue Torch Medical Technologies Inc Vitruvian Robotic Diagnostics Platform for Cancer Surgery Advancement   $ 213,900.00
BrainScope Company Inc BrainScope Ahead M-100 $ 244,479.24  
CCC Diagnostics, LLC Pharmacodiagnostic Molecular Test Panels to Optimize Chemotherapy Selection $ 244,479.25  
Celadon Laboratories Inc. Molecular Diagnostics for Tuberculosis and African-American Public Health. $ 151,820.50 $ 92,658.74
Celek Pharmaceuticals LLC Development of CEL-031, a targeted therapeutic for non-muscle invasive bladder cancer.   $ 38,783.80
Celek Pharmaceuticals LLC Development of CEL-021 for the treatment of interstitial cystis/painful bladder syndrome $ 500.00 $ 19,592.50
Celek Pharmaceuticals LLC Development of CEL-011, an innovative bladder cancer therapy $ 18,281.98 $ 17,294.89
Cellex, Inc Qflu Influenza Diagnostic and Drug Resistance Combo Tes $ 114,051.38 $ 130,427.87
Cellex, Inc. A Quantitative Bacterial Vaginosis Test for Point-of-Care Use $ 139,396.13 $ 105,083.12
Cellona Therapeutics, Inc CT-10, a new class of compound and targeted cancer drug   $ 244,479.24
Cellphire, Inc. Cellphire platelet Stabilization Therapeutic $ 244,479.25  
Celsion Corporation ThermoDox®-A heat activated Liposomal Encapsulation of Doxorubicin to treat HCC $ 244,479.24  
Centegen, Inc A Novel Approach to Treat Staphylococcus Aureus Infections (Including MRSA) $ 65,541.67 $ 178,937.58
Centegen, Inc. A Novel Vaccine to Prevent Staphylococcus Aureus Infections (Including MRSA) $ 8,583.34 $ 42,375.00
CHAMPIONS BIOTECHNOLOGY INC Development of Single Chain Antibody Fragment Targeting Mutant p53 for the Treatment of Cancer $ 140,927.00 $ 103,552.25
Champions Biotechnology, Inc Development of Personalized Tumorgraft Models to Identify Biomarkers and Guide Personalized Cancer Therapies $ 118,653.50 $ 124,142.00
Champions Biotechnology, Inc. Development of Small Molecule Autotaxin Inhibitor Bithionol for the Treatment of Cancer $ 147,870.00 $ 96,609.25
Champions Biotechnology, Inc. Development of a Novel Predictive Preclinical Tumorgraft Platform to Enhance and Accelerate Oncology Drug Development $ 244,479.25  
Champions Biotechnology, Inc. Development of Irinophore-C™  a Novel Nanoparticle Formulation of Irinotecan as an Anti-Cancer Therapy $ 118,803.50 $ 125,675.75
Champions Biotechnology, Inc. Development of Small Molecule Tubulin Inhibitor SG410 for the Treatment of Cancer $ 190,057.50 $ 54,421.75
Clarassance, Inc. Recombinant human CC10 protein for prevention of neonatal BPD $ 77,769.00 $ 166,710.24
Columbia Biosystems Inc Point-of-Care Diagnostics of Infectious Diseases Using Molecularly Imprinted Polymers $ 131,580.00 $ 105,044.00
Cordex Systems, LLC Development of the Cordex Cardiovascular Device   $ 222,606.00
Correlogic Systems Inc Development of diagnostic Multi-variate Assays for Ovarian and Breast Cancers $ 244,479.24  
Corridor Pharmaceuticals, Inc The therapeutic application of C-122 in Pulmonary Arterial Hypertension (PAH) $ 244,479.24  
Corridor Pharmaceuticals, Inc Therapeutic application of Arginase inhibitors for the treatment of endothelial dysfunction $ 244,479.24  
CSA Medical, Inc. TruFreeze Spray Cryotherapy Therapeutic Agent Delivery Platform $ 244,479.24  
Cytlmmune Sciences, Inc Pegylated Colloidal Gold Nanoparticles: The Core of a Family of Novel Nanomedicines $ 244,479.25  
DioGenix Inc Development of a Blood Test for the Early Detection of Multiple Sclerosis $ 244,479.24  
Entremed Inc. ENMD-2076 $ 244,479.24  
ExonHit Dx21 $ 244,479.25  
ExonHit Therapeutics, Inc. Program 107 $ 3,253.50 $ 79,222.00
FASgen, Inc. Treatment of Recurrent Ovarian Cancer $ 244,479.25  
FLAVORx, Inc. & Subsidiary Medicinal Compliance $ 71,098.00 $ 76,925.50
Functional Genetics, Inc Development of a Broad Spectrum Antiviral Antibody Therapeutic Targeting TSG 101 $ 244,479.24  
Functional Genetics, Inc Development of a Broad Spectrum Small Molecule Antiviral Therapeutic Targeting TSG-101 $ 244,479.24  
Fyodor Biotechnologies Inc Urine Malaria Test (UMT) $ 94,584.27 $ 149,894.98
GenArraytion Inc Development of Biomarkers for Clinical Assessment of Occult Infections $ 93,159.50  
GeneCopoeia, Inc. Plasmepsin V Inhibitor Therapeutics for Malaria Infection   $ 223,750.00
GeneCopoeia, Inc. p53 Fusion Protein Therapeutics for Pancreatic Liver Cancer $ 244,479.25  
GeneCopoeia, Inc. Mutant MicroPlasmin Therapeutics $ 244,479.25  
GeneCopoeia, Inc. Recombinant alpha 1-Antitryspin Therapeutics $ 244,479.25  
GenVec, Inc. TNFerade™ Biologic $ 244,479.25  
Gliknik Inc GL-2045, A stradomer for the treatment of ITP, RA other Chronic Autoimmune diseases $ 244,479.24  
Gliknik Inc Clinical stage immunonmodulators GL-0810 and GL-0817 for the treatment of cancer $ 8,574.00 $ 235,905.24
Gliknik, Inc GB-2542, a stradobody for the treatment of breast cancer and other cancers $ 236,068.50 $ 8,410.74
Glycomimetics, Inc GMI-1070 $ 244,479.25  
Glycotex, Inc. GLYC-101 Gel investigational product for treatment of acute and chronic wounds $ 132,917.50 $ 111,561.74
Hitech Analytical and Diagnostic Solutions LLC Prognostic Test Development for Recurrent Spontaneous Abortions and Viable Pregnancy $ 10,700.00  
Iatrica, Inc Dev. Of novel tumor-targeted antibody-based fusion proteins for immunotherapy of cancer $ 195,392.00 $ 49,087.25
ILSbio, LLC. Development of Universal Research Specimen Sets $ 190,293.80 $ 54,185.44
Imagilin Technology LLC Novel aproach to treat autoimmune hemolytic anemia {AIHA}, an autoimmune disease. $ 110,000.00 $ 134,479.25
Imperium, Inc. Speckle Free C-scan Ultrasound Video Imaging Camera for Clinical Diagnostics $ 141,524.00 $ 102,955.25
ImQuest BioSciences, Inc Carbendazim/Benzamidazoles Broad Based Anti-Tumor Agent Project $ 50,000.00 $ 194,479.25
ImQuest BioSciences, Inc Novel Carbamate-based HIV Replication InhibitorProject $ 50,000.00 $ 194,479.25
ImQuest BioSciences, Inc Novel DNA Oligonucleotide development as a Topical Microbicide (ISIS 5320) Project $ 244,479.25  
ImQuest BioSciences, Inc Novel Pyrimidinedione Small Molecule as a Topical Microbicide Project $ 244,479.25  
ImQuest BioSciences, Inc PG 301029 Anti-HCV Program $ 64,794.50 $ 179,684.75
ImQuest Pharmaceuticals Inc Novel Piperazine Project $ 70,525.00 $ 173,954.25
ImQuest Pharmaceuticals, Inc. Novel Pyrimidinedione Project-IQP0410 $ 244,479.25  
Infinite Biomedical Technoliogies, LLC. EEG headband for Automated Seizure Detection with Telemedicine Review $ 208,417.84 $ 36,061.41
Infinite Biomedical Technologies Cortical Health Index Monitor - Regulatory Approval $ 143,724.63 $ 79,462.56
Infinite Biomedical Technologies, LLC Laser Speckle Imaging to Study Brain Tumor Vasculature $ 72,586.82 $ 14,467.76
Infinite Biomedical Technologies, LLC A dexterous prosthetic controller for multi-fingered hands $ 165,848.70 $ 78,630.55
Infinite Biomedical Technologies, LLC. Neonatal Neurological Monitor - Regulatory Approval $ 244,479.25  
InfraTrac, Inc Protecting the Intergrity of the Drug Supply with Spectroscopic Verification $ 19,062.50 $ 33,650.00
Innovative Biosensors, Inc Development of a CANARY® - based rapid clinical diagnostic test for MRSA. $ 244,479.25  
Integrated Biotherapeutics, Inc. Therapeutics for Staph aureus and related toxic shock $ 244,479.24  
Integrated Biotherapeutics, Inc. Staphylococcus aureus Vaccine Program $ 74,250.77 $ 100,000.00
Kirkegaard & Perry Laboratories, Inc In vitro-diagnostic grade an tibodies for whole bacteria capture and detection $ 90,899.15 $ 153,580.09
Lentigen Corporation LG1041 Breakthrough Therapy/Cure for Hunter's Syndrome   $ 132,289.85
Lentigen Corporation LG911 Novel Broad-Spectrum Cancer Therapy for Solid Tumors $ 5,833.05 $ 57,088.32
Lentigen Corporation LG912 Novel Hepatitis C/Liver Cancer Therapeutic Vaccine $ 11,988.24 $ 82,594.26
Lentigen Corporation Advanced Bioproduction Platform for US Military $ 138,997.66 $ 79,624.52
Lentigen Corporation LG611 High Potential Pandemic Influenza Vaccine $ 244,479.25  
Lentigen Corporation LG723 Novel Anticancer Melanoma Therapy $ 4,601.27 $ 223,730.34
Lentigen Corporation LG631 Novel Therapy for Glioblastoma   $ 142,487.08
Lentigen Corporation LG970 Next Generation Preventative Vacine for HIV/AIDS $ 1,655.14 $ 109,936.87
Luminescent MD, LLC Development of Fully Automated Chemiluminescent Enzyme Immunoassay Systen $ 10,643.85 $ 4,930.09
MacroGenics Inc MGAH22 $ 244,479.25  
MacroGenics Inc mAb Pipeline $ 244,479.25  
MacroGenics, Inc T-Dart $ 244,479.25  
MacroGenics, Inc MGAWN1 $ 244,479.25  
MacroGenics, Inc. Cancer Stem Cells $ 244,479.25  
MacroGenics, Inc. Teplizumab $ 244,479.25  
MacroGenics, Inc. MGA271 $ 244,479.25  
Mastix Medica LLC Effect of chitosan gum on serum phosphate in ESRD patients   $ 19,371.00
MaxCyte Inc. MaxCyte Cell Modification Technology Platform for Therapeutic Development and Discovery $ 244,479.25  
MetaMorphix, Inc. Myostatin Inhibitors to Accelerate Tissue Growth $ 113,923.50 $ 39,353.50
NABI BIOPHARMACEUTICALS DEVELOPMENT OF NICVAX $ 244,479.24  
NEURALSTEM INC Development of an allogeneic human neural stem cell product for treatment of ALS $ 244,479.25  
Neuralstem, Inc Development of an IGF1-expressing human neural stem cell product for treatment of ALS $ 165,463.00 $ 79,016.25
Neuralstem, Inc. Neurogenic Compound to Treat Major Depression $ 165,463.50 $ 79,015.75
Neuronascent Inc Novel Small-Molecule Neurogenic Preclinical Candidates as Therapeutics for Chronic Neurodegenerative Disorders $ 43,081.00 $ 63,025.00
NEW HORIZONS DIAGNOSTICS CORPORATION A simple and Rapid Diagnostic Test for Pancreactic Cancer Using Novel Serum Biomarkers $ 66,053.50 $ 137,000.00
New Horizons Diagnostics Corporation The use of phage lytic enzymes as non-resistant anti-microbials $ 99,080.50 $ 145,398.74
Northwest Biotherapeutics Inc Clinical Development of DCVaz $ 244,479.25  
Northwest Biotherapeutics Inc Development of DCVax-Direct $ 244,479.25  
Novavax, Inc. Respiratory Syncytial Virus Vaccine Development $ 244,479.25  
Novavax, Inc. Varicella-Zoster Virus Vaccine Development $ 69,000.00 $ 175,479.25
Novavax, Inc. Pandemic Influenza Vaccine Development $ 244,479.25  
Novavax, Inc. Seasonal Influenza Vaccine Development $ 244,479.25  
Ocular Proteomics LLC The Vitreous Proteome $ 244,479.24  
OpGen,Inc Rapid Microbial Infection Identification $ 244,479.25  
OriGene Technologies, Inc OriGene Autoantibodies Early Screening Test for Ovarian Cancer $ 244,479.25  
Osiris Therapeutics, Inc. Prochymal $ 244,479.25  
Paragon Bioservices,Inc Induction of Hypoxia Tolerance at the Cellular Level   $ 244,479.25
Pearl Lifescience Partners, LLC Bioengineering host cells to produce superior vaccines against envelop viruses $ 87,630.92 $ 156,848.32
PharmAthene Inc recombinant BChE Alternate Expression System Development Program $ 1,040.00 $ 114,705.65
PharmAthene Inc Protexia Drug Development Program $ 244,479.25  
PharmAthene, Inc rPA Drug Development Program $ 7,500.00 $ 235,580.41
PharmAthene, Inc. Valortim Biologic Development Program $ 244,479.25  
PlantVax Inc BChE $ 45,902.00 $ 58,324.00
PlantVax, Inc MA b $ 61,936.50 $ 45,893.50
Profectus BioSciences Inc NF-kB Rel inhibitors for the treatment of Cancer $ 244,479.25  
Profectus BioSciences, Inc Therapeutic and prophylactic vaccines against HIV $ 244,479.25  
Psyadon Pharmaceuticals, Inc Ecopipam for the Treatment of Lesch-Nyhan Disease $ 244,479.24  
Quantum Medical Metrics LLC Phase-contrast enhanced X-ray imaging system for small joint of hand $ 4,000.00 $ 80,500.00
RAFAGEN, Inc. Development of cancer-selective replication-competent retrovirus therapy for neuroblastoma $ 118,375.82 $ 126,103.42
Raland Technologies LLC RxFusion Infusion Switch Device $ 25,500.00 $ 218,979.25
RAPID LABORATORIES, INC. Chemokine Receptor Antagonists That Treat HIV Viral Reservoirs & Chronic Inflamm. Disease $ 244,479.24  
RegeneRx Biopharmaceuticals Inc RGN-352 for Cardiac and Neuronal Tissue Regeneration $ 244,479.25  
RegenexRx Biopharmaceuticals Inc RGN-137 for Dermal Tissue Regeneration $ 244,479.25  
RegenRx Biopharmaceuticals Inc RGN-259 for Corneal Tissue Regeneration and Other Anterior Eye Pathologies $ 244,479.25  
RetroTherapy LLC Reprograming gene expression in stem cells $ 114,605.54 $ 129,873.71
Rexahn Pharmaceuticals, Inc Zoraxel $ 154,426.35 $ 90,052.89
Rexahn Pharmaceuticals, Inc. Anti-Cancer Drugs $ 244,479.24  
Rexahn Pharmaceuticals, Inc. Poly HPMA System for Drug Delivery $ 33,239.23 $ 55,460.59
Rexahn Pharmaceuticals, Inc. Serdaxin $ 244,479.24  
Sanaria, Inc. Live Attenuated Plasmodium Falciparum Sporozoite (malaria) Vaccine $ 244,479.24  
Seguro Surgical Inc. Post Operative Adhesion reduction $ 20,163.50 $ 118,310.50
Sequella Inc SQ641: A Novel Translocase-1 Inhibitor for Treatment of Mycobacterial Infections $ 244,479.25  
Sequella, Inc B-SMART: a novel rapid platform technology to detect bacterial drug resistance $ 83,717.50 $ 103,915.00
Sequella, Inc. SQ109: A Potential Foundation Drug for a New Regimen to Cure Tuberculosis $ 244,479.25  
Sequella,Inc SQ609:A Potent New Drug for Treatment of multidrug-resistant Tuberculosis $ 162,295.50 $ 25,927.50
Sequoia Pharmaceuticals Inc Development of Novel HCV Protease Inhibitors $ 244,479.24  
Sequoia Pharmaceuticals, Inc. Development of Pharmacokinetically Enhanced Fixed Dose Combinations for HIV and Cancer $ 244,479.24  
Sequoia Pharmaceuticals, Inc. Clinical  Development of a Pharmacokinetic Enhancer $ 244,479.24  
Shreis Scalene Sciences, LLC The Cythotron-a novel, stand-alone therapeutic device utilizing non-ionizing RFQMR to treat cancer and improve drug targeting & delivery through nano-permeabilization   $ 244,479.25
SLEEP METHODS, INC. Obstructive Sleep Apnea Therapeutic System $ 108,553.00 $ 135,926.25
Sleep Solutions Inc NovaSom II $ 75,705.00 $ 168,774.25
Sucampo Pharma Americas, inc A Study of the Efficacy and Safety of Lubiprostone in Patients with OBD   $ 244,479.25
SUCAMPO PHARMA AMERICAS, INC A STUDY OF COBIPROSTONE FOR THE PREVENTION OF NSAID-INDUCED ULCERS $ 244,479.25  
SUCAMPO PHARMA AMERICAS, INC. UNOPROSTONE ISOPROPYL FOR DRY AMD RETINITIS PIGMENTOSA $ 244,479.25  
Supemus Pharmaceuticals, Inc Zalvari™ A new therapy to treat persistent conduct problems in children with ADHD $ 244,479.25  
Supernus Pharmaceuticals Inc A Novel Non-Stimulant Treatment for ADHD $ 244,479.25  
Symphony Evolution Inc XL647 RTK Cancer Therapeutics $ 244,479.24  
Symphony Evolution, Inc XL784 for Abominal Aortic Aneurysm $ 157,998.50 $ 86,480.74
Synaptic  Research, LLC Development of Clostridial toxin based therapies for Botulism, Cancer, AKS, and Stem Cells $ 63,349.27 $ 123,191.53
SynerGene Therapeutics, Inc A Novel Tumor-targeting Cancer Nanomedicine Eliminates, and Prevents Recurrence of, Solid Tumors $ 140,177.93 $ 104,301.32
Synergy America Inc Product Development for Invasive Pneumoccal Diseases $ 244,479.25  
TDP Biotechnology YK-4-279 as a Novel Therapy for Cancer   $ 159,070.00
Tetracore, Inc FAS- Detect ELISA Test $ 181,204.18 $ 63,275.06
Theranostics Health Inc. Novel Diagnostic Test for Directing Molecular Targeted Therapies in Metastatic Cancer $ 151,670.50 $ 92,808.75
Therataxis LLC Brain Disease Treatment Simulator $ 14,150.00  
TissueGene, Inc Noninvasive regenerative therapy for the treatment of osteoarthritis $ 244,479.24  
Trevigen Inc Knockdown Cell Lines $ 134,640.52 $ 88,851.69
Trevigen Inc PARP in vivo pharmacodynamic Assay II $ 58,906.64 $ 5,227.27
Trophogen Inc Development of TSH Superagonist Analogs for Diagnosis and Treatment of Thyroid Cancer $ 244,479.24  
TROPHOGEN, INC. Development of FSH Superagonist Analogs for Infertility and Ovarian Cancer $ 6,969.22 $ 196,483.90
Validus Biopharma, Inc. Development of VBP15 for the treatment of Duchenne Muscular Dystrophy $ 81,728.23 $ 162,751.02
Vallinex Inc VNX-4975 for the treatment of severe knee osteoarthritis and Morton's neuroms   $ 244,479.25
Vanda Pharmaceuticals Inc. Development VZP-758 compound to treat Raynaud's Phenomenon $ 244,479.25  
Vanda Pharmaceuticals Inc. Development of tasimelteon to treat Non-24-Hou Sleep/Wake Disorder in blind individuals. $ 244,479.25  
Vapotherm Inc. Adaptive Oxygen Control $ 3,664.54 $ 63,540.52
Vapotherm Inc. Nasal Drug Delivery $ 18,358.20 $ 62,554.29
VectorLogics, Inc Cancer Virotherapeutics $ 244,479.24  
Vesta Therapeutics Grafting Strategies for Liver Cell Therapies $ 225,856.25 $ 18,623.00
Vesta Therapeutics Allogeneic Hepatic Progenitor Cell Therapy for Liver Diseases $ 244,479.25  
Viracine Therapeutics Corporation NoVR $ 50,575.10 $ 193,904.15
ViroDefense Inc AntiViral Drug for Enterovirus 71 Neurologic Infections $ 244,479.24  
ViroDefense Inc Antiviral drug Essential for Polio Eradication $ 244,479.25  
VIRxSYS Corporation Lexgenleucel-T $ 244,479.25  
VIRxSYS Corporation VRX1273 $ 244,479.24  
VIRXsys Corporation VRX1243 $ 211,840.00 $ 32,639.25
Weinberg Medical Physics, LLC Ultra Fast Magnetic Field Generator $ 202,673.22 $ 41,806.02
Weinberg Medical Physics, LLC MRI-Compatible PEM Scanner   $ 109,350.06
Weinberg Medical Physics, LLC Real-Time Guidance System for Monitoring Proton Therapy $ 51,756.97 $ 87,316.04
Wellstat Biologics Corporation PV701 Oncolytic Virus for the Treatment of Cancer $ 244,479.24  
WELLSTAT DIAGNOSTICS LLC Electrochemiluminescent based RNA detection platform for POC diagnosis of cancers and pathogens $ 244,479.24  
WELLSTAT DIAGNOSTICS LLC Rapid POC blood-based diagnostic test for nonalcoholic fatty liver disease and steatohepatitis $ 80,232.00 $ 164,247.24
Wellstat Diagnostics LLC Rapid point-of-care Lyme disease blood-based diagnostic test   $ 85,974.50
WellStat Diagnostics, LLC A novel antibiotic combination to treat infections of drug resistant Staphylococcus aureus. $ 82,262.00 $ 162,217.24
WELLSTAT IMMUNO THERAPEUTICS LLC WIT-301 for prevention and treatment of Type 1 Diabetes $ 79,667.00 $ 87,203.00
Wellstat Immuno Therapeutics LLC WIT-201: Tolerogenic protein for treatment of multiple sclerosis   $ 66,653.00
WELLSTAT IMMUNO THERAPEUTICS LLC ZPS pllysaccharide for treatment of inflammatory diseases $ 244,043.50 $ 435.74
Wellstat Ophthalmics Corporation Sustained Delivery of Novel Therapeutics for the Treatment of Ocular Diseases $ 244,479.24  
WELLSTAT THERAPEUTICS CORP pn2107 FOR THE TREATMENT OF HYPERURICEMIA AND GOUT $ 244,479.25  
Wellstat Therapeutics Corporation Invitro-generated T-progenitor cells for T-cell reconstitution in hematopoietic stem cell transplantation $ 42,781.50 $ 178,795.00
WELLSTAT THERAPEUTICS CORPORATION PN403 for the treatment of mitochondrial disease and Alzheimer's disease $ 244,479.25  
Wellstat Therapeutics Corporation pn401 FOR THE Treatment of Cancer Patients $ 244,479.25  
WELLSTAT THERAPEUTICS CORPORATION PN951 for ex vivo expansion of cord blood stem cells for transplants $ 244,479.25  
Wellstat Vaccines LLC A novel Neisseria meningitidis Group B polysaccharide Conjugate vaccine $ 156,919.50 $ 87,559.74
WELLSTAT VACCINES LLC Neisseria meningitidis Groups C and Y/Haemophilus influenzae type b conjugate vaccine $ 176,142.50 $ 68,336.74
Xcision Medical Systems, LLC Method and Equipment for Image-Guided Stereotactic Radiosurgery of Breast Cancer $ 244,479.24  
Zyngenia, Inc Single protein, multi-specific therapeutics for Cancer $ 244,479.24  
Zyngenia, Inc. Single, protein, multispecific therapeutics in Chronic Autoimmune and Inflammatory Diseases $ 244,479.24  

Rate the Small Business and Self-Employed Website

Page Last Reviewed or Updated: 21-Oct-2014